Healthy.io, a Tel Aviv-based developer of software for smartphone-based at-home urinalysis, announced on Sept. 12 the close of its Series C funding round, totaling $60 million, with participation from Samsung's innovation arm.
In addition to the fundraise, which will be used to expand the startup's product development and global reach, Healthy.io was also granted marketing authorization from the FDA for its diagnostic software. The urinalysis uses machine learning to transform a smartphone camera into a clinical-grade medical device, able to aid in the diagnosis of chronic kidney disease.
The startup also announced the addition of Gary Loveman, PhD, to its board of directors. Most recently, Dr. Loveman served as executive vice president of Aetna and president of Healthagen, the company's consumer health and services business.
"Today, too many patients face barriers to care, leading to missed appointments, undiagnosed conditions, and increased visits to the emergency room or hospital. Healthy.io is establishing itself as a leader in a new world of broader, decentralized access to care without compromising on clinical quality," Dr. Loveman said in a statement.